MemorialCare Long Beach Medical Center will participate in two multinational clinical trials investigating the efficacy and safety of two different anti-viral treatments designed to reduce the severity as well as possibly halt the spread of COVID-19 in both hospitalized and ambulatory patients. Led by Principal Investigator Jimmy Johannes, MD, the Southern California-based hospital evaluates REGN-COV2, the monoclonal antibody cocktail treatment developed by Regeneron Pharmaceuticals. Designed to target the “spike” protein associated with SARS-CoV-2, the virus behind COVID-19, this is how the virus grabs on to and penetrates healthy cells. These advanced monoclonal antibodies were engineered by Regeneron to halt the virus replication process and hence the actual spread of the pathogen. TrialSite has written extensively about the investigational therapy known as REGN-COV2.
Long Beach & LA County COVID-19
MemorialCare Long Beach Medical Center is located in Long Beach, California, in Los Angeles County. With about 15 million people in both Los Angles and Orange County, the hospital sits in the southern part of Los Angeles County right near the Orange County border. LA County has 256,148 reported COVID-19 cases with 6,303 deaths thus far. Although Los Angeles County appears to be through the worst of the pandemic, that could change given post-Labor Day numbers, warned Barbara Ferrer, public health director, recently.
Presently, LA County is in the highly restrictive “purple” level of California’s four-tier virus tracking roadmap. Average new cases per 100,000 total 8.1, and the County must meet the threshold of 7 cases per 100,000 to move to a less restrictive tier.
Long Beach Medical Center Clinical Trial Activity
MemorialCare Long Beach Medical Center was actively involved with the expanded access studies of the drug Remdesivir and convalescent plasma. Of course, the U.S. Food and Drug Administration (FDA) recently provided Emergency Use Access for both of those treatments for patients hospitalized with COVID-19.
Principal Investigator Point of View
Dr. Johannes recently commented, “One of the most important ways our immune system fights infections from viruses is by making monoclonal antibodies against the virus. Because of this, the use of monoclonal antibodies against SARS-CoV-2 is considered to be a very promising approach for treating COVID-19.” He continued, “Antibody treatments are a proven treatment approach with a strong history of safety and tolerability. We use monoclonal antibodies to treat conditions like autoimmune disease, various cancers, and asthma. Nevertheless, despite our optimism for the efficacy and safety of monoclonal antibodies to treat COVID-19, it is imperative that we prove that this approach is truly effective and safe with these randomized controlled trials.”
MemorialCare Long Beach Medical Center
MemorialCare Long Beach Medical Center is the flagship hospital of the MemorialCare Health System. Established as Seaside Hospital in 1907 it was incorporated as Seaside Memorial Hospital on June 23, 1937. By 1960, it moved to its present location. The hospital is accredited by the Joint Commission.
This center is one of only 3 hospitals in California with a 320 CT Scanner and preventive technology and programs such as the Electromagnetic Navigation Bronchoscope (ENB) and the Division of Interventional Neuroradiology.
The Hospital includes facilities such as the MemorialCare Heart and Vascular Institute, MemorialCare Todd Cancer Institute, the MemorialCare Rehabilitation Institute, and much more. With 420 beds, MemorialCare maintains a comprehensive Research operation. There are currently over 300 ongoing research projects at the MemorialCare hospital focusing on cancer, heart disease, orthopedics, infectious diseases, gynecology, obstetrics, urology and more.